MGI and OncoDNA join forces to offer laboratories a streamlined NGS workflow for implementing Comprehensive Genomic Profiling (CGP) OncoDEEP® Kit in clinical practice

MGI (MGI Tech Co., Ltd. or its subsidiaries, together referred to MGI), a company committed to building core tools and technologies that drive innovation in life science, today announced the collaboration with OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of cancer and genetic diseases.

Is retroelement-based gene editing a safer alternative to CRISPR-Cas approaches?

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.

October 27, 2023

BeiGene’s Brukinsa bags fifth FDA approval, likely positioning it for continued sales growth

BeiGene’s Brukinsa has clinched a fifth US green light in B-cell malignancies — this time for follicular lymphoma (FL) — further expanding its reach in

March 8, 2024

Undetected Cognitive Impairment in Primary Care

Undetected cognitive impairment in primary care continues to be a nationwide problem, recent studies showed. “Unrecognized cognitive impairment and dementia is a major problem in

May 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.